EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC

Tugce Telli iD, Leonor Lopes, Madeleine Karpinski, Kim M Pabst, Viktor Grünwald, Kuangyu Shi, Boris Hadaschik, Claudia Kesch, Lale Umutlu, Ken Herrmann, Robert Seifert, Wolfgang P Fendler

European Journal of Nuclear Medicine and Molecular Imaging · 2025-07 · 52 (9) · 3199-3210

DOI: 10.1007/s00259-025-07198-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.03.2025. Verfasst von Tugce Telli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. tugce.telli@uk-essen.de. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Lutetium. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To improve [ 177 Lu]Lu-Prostate-specific membrane antigen therapy (LuPSMA) selection, this study investigates the prognostic value of PSMA and 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG)-PET in metastatic castration-resistant prostate cancer (mCRPC) patients considered for LuPSMA therapy.

Methods

We conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [ 18 F]FDG-PET/CT. Of these, 104 patients (68.4%) underwent LuPSMA therapy, while 48 (31.6%) received other standard of care (SOC). PET/CT analyses included visual assessment and semiquantitative measurements. Clinical and laboratory parameters were recorded. Overall survival (OS) and PSA response (decline > 50%) were primary and secondary endpoints, respectively.

Results

Baseline [ 18 F]FDG-derived total tumor volume was the only independent predictor of overall survival both in patients subsequently treated with LuPSMA (HR 1.28 [95%CI 1.02—1.61]; p = 0.03) or in those under other SOC (HR 1.61 [95%CI 1.02—2.56]; p = 0.04), respectively. In other SOC patients, additional independent predictors of OS were total lesion PSMA uptake (PSMA-TL; HR 1.14 [95%CI 1.03–1.26]; p = 0.01), [ 18 F]FDG mean SUV (HR 20.88 [95%CI 1.2–364.74]; p = 0.04), and [ 18 F]FDG total lesion glycolysis (HR 1.61 [95%CI 1.02–2.56]; p = 0.04). In LuPSMA patients, PSMA-PET SUVmean was a significant independent predictor of PSA decline ≥ 50% (OR 2.97 [95%CI 1.27–8.16]; p = 0.02).

Conclusion

PSMA-PET and [ 18 F]FDG-PET provide imaging biomarkers of outcome in candidates for LuPSMA. FDG-PET total tumor volume was an independent predictor of overall survival in candidates for LuPSMA therapy, irrespective of subsequent treatment decision. PSMA-PET SUVmean was associated with biochemical response to LuPSMA. Dual tracer imaging should further be assessed in prospective trials for mCRPC treatment guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Prostatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyLutetiumGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedMiddle AgedPrognosisRetrospective StudiesAged, 80 and overRadiopharmaceuticalsTreatment OutcomeRadioisotopes

Stichwörter der Autor:innen

BiomarkersFDGPSMAPrognosticsProstate cancer

Substanzen

Fluorodeoxyglucose F18LutetiumGlutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, SurfaceLutetium-177RadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. tugce.telli@uk-essen.de.
  • German Cancer Consortium (DKTK), Partner Site, Partnership Between DKFZ and University Hospital Essenaq , Essen, Germany. tugce.telli@uk-essen.de.
  • West German Cancer (WTZ), Essen, Germany. tugce.telli@uk-essen.de.
  • Department of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
  • Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium (DKTK), Partner Site, Partnership Between DKFZ and University Hospital Essenaq , Essen, Germany.

ORCID-Profile: Tugce Telli

Förderung

  • Universitätsklinikum Essen

Zitieren

APA

Telli, T., Lopes, L., Karpinski, M., Pabst, K. M., Grünwald, V., Shi, K., Hadaschik, B., Kesch, C., Umutlu, L., Herrmann, K., Seifert, R., & Fendler, W. P. (2025). Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 52(9), 3199-3210. https://doi.org/10.1007/s00259-025-07198-y

Vancouver

Telli T, Lopes L, Karpinski M, Pabst KM, Grünwald V, Shi K, et al. Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(9):3199-3210. doi:10.1007/s00259-025-07198-y

BibTeX
@article{Telli2025,
  author = {Telli, Tugce and Lopes, Leonor and Karpinski, Madeleine and Pabst, Kim M and Grünwald, Viktor and Shi, Kuangyu and Hadaschik, Boris and Kesch, Claudia and Umutlu, Lale and Herrmann, Ken and Seifert, Robert and Fendler, Wolfgang P},
  title = {Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {9},
  pages = {3199--3210},
  doi = {10.1007/s00259-025-07198-y}
}
Kostenlos starten →